Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 43Carcinoma, Hepatocellular 19Rectal Neoplasms 10Colonic Neoplasms 10Neoplasm Metastasis 9Gastrointestinal Stromal Tumors 8Sarcoma 5Ovarian Neoplasms 5Melanoma 4Cholangiocarcinoma 4Pancreatic Neoplasms 3Osteosarcoma 3Liver Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1

Interventions

Octreotide 4Everolimus 4Capecitabine 3Temozolomide 2Melphalan 2Biological Therapy 2vatalanib 1temsirolimus 1romidepsin 1regorafenib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Filgrastim 1Cytokines 1Complementary Therapies 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Islet Cell × regorafenib × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡